Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Belgium

- PMLiVE

Pfizer and viral infection specialist ReViral agree on $525m deal

According to the deal, Pfizer will acquire ReViral for a total of up to $525m

- PMLiVE

FDA grants Pfizer/BioNTech expanded EUA for an additional COVID-19 vaccine booster

The second booster authorisation is for those aged 50 years and older to promote high levels of protection against COVID-19 in the most vulnerable groups

- PMLiVE

Pfizer receives Breakthrough Therapy Designation from FDA for RSV vaccine candidate

There are currently no preventative, therapeutic or vaccine options for older adults diagnosed with RSV

- PMLiVE

Pfizer agrees to supply UNICEF with up to 4 million courses of oral COVID-19 treatments

The deal is set to benefit to 95 low- and middle-income countries, pending authorisation or approval

- PMLiVE

CBI launches new Health Council as part of its Seize The Moment 2030 vision

The CEO forum has been designed to bring together business, government and civil society to improve health outcomes across the UK

- PMLiVE

Pfizer highlights need for fourth dose of COVID-19 vaccine to FDA

While new study published in The Lancet shows COVID-19 mortality rate is almost three times higher than previously thought

- PMLiVE

Pfizer finalises $6.7bn acquisition of Arena Pharmaceuticals

Arena is a clinical stage company developing innovative potential therapies for immuno-inflammatory diseases

- PMLiVE

Pfizer begins phase 2/3 study of oral COVID-19 treatment in paediatric patients

The phase 2/3 trial involves around 140 patients under the age of 18

- PMLiVE

Pfizer’s Lorviqua receives EC approval for treatment of advanced lung cancer

The approval is based on the phase 3 CROWN trial comparing Lorviqua with Xalkori

- PMLiVE

Pfizer’s Paxlovid receives positive opinion from CHMP

If authorised, the drug would be the first COVID-19 oral treatment recommended in the EU

- PMLiVE

Pfizer and BioNTech start clinical trial for Omicron-based COVID-19 vaccine

The clinical trial involves adults aged 18 to 55 who received an Omicron-based vaccine candidate as part of a two-dose primary series, as well as a booster

- PMLiVE

Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis

The FDA based its approval on results from a clinical trial programme involving over 1,600 patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links